Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
about
Dinosaurs and ancient civilizations: reflections on the treatment of cancerCombinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current statusRapid induction of orthotopic hepatocellular carcinoma in immune-competent rats by non-invasive ultrasound-guided cells implantation.Inhibition of tumors cell growth in osteosarcoma-bearing SD rats through a combination of conventional and metronomic scheduling of neoadjuvant chemotherapy.Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.Hepatocellular carcinoma: insight from animal models.Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.Hesperetin induces the apoptosis of hepatocellular carcinoma cells via mitochondrial pathway mediated by the increased intracellular reactive oxygen species, ATP and calcium.SNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide.The interconnectedness of cancer cell signaling.Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancersWentilactone B induces G2/M phase arrest and apoptosis via the Ras/Raf/MAPK signaling pathway in human hepatoma SMMC-7721 cells.Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinomaCo-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular CarcinomaLongikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells.Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.Aspafilioside B induces G2/M cell cycle arrest and apoptosis by up-regulating H-Ras and N-Ras via ERK and p38 MAPK signaling pathways in human hepatoma HepG2 cells.Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts.Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integrationFuzheng Qingjie granules potentiate the anticancer effect of cyclophosphamide by regulating cellular immune function and inducing apoptosis in Hepatoma 22 tumor-bearing mice.Circulating perivascular progenitors: a target of PDGFR inhibition.Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma
P2860
Q24628746-E9B38C26-DC0B-420D-A41A-A9CD7E223562Q27001560-EFE60227-0BF8-4A3F-9D2B-D8D932378FEBQ30986337-12EA3142-5440-4E01-9714-6B6024C369B6Q33557868-B6FADBFD-83E5-40A4-85F7-DBBEE2F42C59Q34300621-8301B7CE-96B2-497B-AF75-CBFCECC4EBE7Q34497992-B570FAB0-B5BD-4877-8888-EEBFE7914993Q34633249-8202E0B8-BB62-4B59-BDFE-344C132F353AQ34633657-D852A48A-273C-4F8B-B381-90352F6FCFBAQ35571150-97607DF4-AFB0-4C65-A87E-7F07F8088A2CQ35618595-93306572-703A-4918-93A9-B8FFC8EB4377Q35669733-D6A9F276-4651-40DC-9049-F10112A67BBEQ35863880-653AEDE1-702C-478B-BCBC-4ECAAF68AED8Q35918752-FC4A5566-DC1D-4279-80B4-5080F8DD9D99Q36973744-3F4578C0-95AF-49FC-A02D-A9E15DD3B135Q37236004-0506164D-156B-4E92-A494-84B76AE240E4Q37245796-3BE3D48D-2390-490D-8A38-8065788F3B04Q37680236-389DE6D4-B8A4-4FA8-959B-4355417C3291Q38889516-B4CA2254-F65E-4FA5-9901-0D6AF5449268Q38909365-226F4C86-9E19-42E5-93D1-3FE1858D2E7DQ39324636-859A75FE-7ED3-445A-8420-968A886F84D8Q39356122-B1304B6E-B4DE-4626-AA70-F7A5CCC9C415Q39501053-AE465FF1-7F51-477B-AF81-206E9D461E77Q40743672-3FE151E1-FECF-4343-B816-F996DC3242A4Q41879186-C3EA89D5-EF15-4114-A7A2-EBAC1B7265BFQ41990987-A1512128-AE40-4D90-8349-1F88BF3BA6B1Q54628938-329EDA16-6198-4B87-8158-1C62D9CF5F12Q58215154-7ED8FE73-8FF7-46A1-98F1-160CF23DF4CA
P2860
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Impact of metronomic UFT/cyclo ...... opic hepatocellular carcinoma.
@ast
Impact of metronomic UFT/cyclo ...... opic hepatocellular carcinoma.
@en
type
label
Impact of metronomic UFT/cyclo ...... opic hepatocellular carcinoma.
@ast
Impact of metronomic UFT/cyclo ...... opic hepatocellular carcinoma.
@en
prefLabel
Impact of metronomic UFT/cyclo ...... opic hepatocellular carcinoma.
@ast
Impact of metronomic UFT/cyclo ...... opic hepatocellular carcinoma.
@en
P2093
P2860
P356
P1433
P1476
Impact of metronomic UFT/cyclo ...... opic hepatocellular carcinoma.
@en
P2093
Christina R Lee
Robert S Kerbel
Terence C Tang
P2860
P304
P356
10.1593/NEO.91872
P577
2010-03-01T00:00:00Z